Cumulus Neuroscience raises £3.25M for at-home EEG clinical trial platform
Summary
Cumulus Neuroscience raised £3.25 million in funding led by Whiterock Finance through its Growth Capital Fund, with participation from the Investment Fund for Northern Ireland managed by Clarendon Fund Managers, Angel CoFund, and Co Fund Northern Ireland. The Belfast-based company develops the NeuLogiq platform, which uses FDA-cleared dry sensor EEG headsets and AI to collect objective brain function data from patients at home for neuroscience clinical trials.
Why it matters
Cumulus Neuroscience addresses a critical bottleneck in neurological drug development by providing objective, quantitative brain function data that traditional assessments cannot capture. Its at-home EEG platform enables remote monitoring of cognition, mood, and language across clinical trials, potentially transforming how pharmaceutical companies evaluate CNS drug efficacy while accelerating development of new therapies for Alzheimer's, Parkinson's, and depression.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial